评估新诊断多发性骨髓瘤患者接受硼替佐米为基础的治疗时的中性粒细胞与淋巴细胞比值。

Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.

出版信息

Cancer Biomark. 2018;22(1):43-48. doi: 10.3233/CBM-170795.

Abstract

BACKGROUND

The neutrophil-to-lymphocyte ratio (NLR) at diagnosis has been identified as an independent prognostic marker in several malignancies. Recently, a few studies have reported that an elevated pretreatment NLR is associated with poor survival among multiple myeloma (MM) patients. However, the role of NLR at diagnosis in patients with MM treated with regimens containing bortezomib has been less explored.

OBJECTIVE

We aimed to investigate the relationships between NLR and overall survival (OS) in newly diagnosed patients receiving bortezomib-based therapy for MM.

METHODS

A total of 76 newly diagnosed patients with MM treated with bortezomib-based regimes were analyzed retrospectively. NLR was calculated from whole blood counts prior to therapy and subsequently correlated with OS.

RESULTS

Complete remission (CR) was seen in 39.2% of patients with NLR < 2.95 compared to 20% in the group with NLR ⩾ 2.95 (P= 0.094). NLR was lower in CR patients in comparison to Non-CR subjects (P= 0.044). Patients with a NLR ⩾ 2.95 experienced inferior median survival compared to those with NLR < 2.95 (4-year OS rates were 30.9% and 64.8%, respectively, P= 0.029). In multivariate analysis, only elevated LDH and IgA MM were factors predicting inferior OS.

CONCLUSIONS

Elevated NLR was associated with poor OS in MM patients receiving induction therapy with bortezomib-based regimens, but it was not an independent prognostic factor in this patient cohort.

摘要

背景

中性粒细胞与淋巴细胞比值（NLR）在多种恶性肿瘤的诊断中被确定为独立的预后标志物。最近，有几项研究报告称，多发性骨髓瘤（MM）患者的预处理 NLR 升高与生存不良相关。然而，在接受硼替佐米为基础方案治疗的 MM 患者中，NLR 对诊断的作用尚未得到充分探索。

目的

我们旨在探讨 NLR 与接受硼替佐米为基础方案治疗的新诊断 MM 患者的总生存期（OS）之间的关系。

方法

回顾性分析了 76 例接受硼替佐米为基础方案治疗的新诊断 MM 患者。在治疗前的全血计数中计算 NLR，随后与 OS 相关联。

结果

NLR<2.95 的患者中完全缓解（CR）率为 39.2%，而 NLR ⩾2.95 的患者中为 20%（P=0.094）。与非 CR 患者相比，CR 患者的 NLR 较低（P=0.044）。NLR ⩾2.95 的患者的中位生存期劣于 NLR<2.95 的患者（4 年 OS 率分别为 30.9%和 64.8%，P=0.029）。多变量分析显示，仅升高的 LDH 和 IgA MM 是预测 OS 不良的因素。